ACR-2316
Not specified (likely solid tumors)
Clinical candidateInternally developed dual WEE1/PKMYT1 inhibitor
Key Facts
Indication
Not specified (likely solid tumors)
Phase
Clinical candidate
Status
Internally developed dual WEE1/PKMYT1 inhibitor
Company
About Acrivon Therapeutics
Acrivon Therapeutics is pioneering a proteomics-based approach to precision oncology with its AP3 platform, which directly measures disease-driving protein activity to overcome the limitations of genomic biomarkers. The company has built a pipeline focused on DNA Damage Response and cell cycle targets, led by the Phase 2 candidate ACR-368, and is developing internally discovered compounds including ACR-2316 (dual WEE1/PKMYT1 inhibitor) and ACR-6840 (CDK11 inhibitor). With operations in Boston and Scandinavia, Acrivon aims to transform cancer treatment by accurately matching therapies to patients most likely to respond, addressing high unmet needs in prevalent solid tumors.
View full company profileTherapeutic Areas
Other Not specified (likely solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| ACR-6840 | Acrivon Therapeutics | Development candidate |